.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,156,823

« Back to Dashboard

Details for Patent: 9,156,823

Title:Antiviral compounds
Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Inventor(s): Bacon; Elizabeth M. (Burlingame, CA), Cottell; Jeromy J. (Redwood City, CA), Katana; Ashley Anne (San Mateo, CA), Kato; Darryl (San Francisco, CA), Krygowski; Evan S. (Washington, DC), Link; John O. (San Francisco, CA), Taylor; James (San Mateo, CA), Tran; Chinh Viet (San Diego, CA), Martin; Teresa Alejandra Trejo (Union City, CA), Yang; Zheng-Yu (Palo Alto, CA), Zipfel; Sheila (San Mateo, CA)
Assignee: Gilead Pharmasset LLC (Foster City, CA)
Filing Date:Nov 16, 2011
Application Number:13/884,578
Claims:1. A compound of formula (I): E.sup.1a-V.sup.1a--C(.dbd.O)--P.sup.1a--W.sup.1a--P.sup.1b--C(.dbd.O)--V.- sup.1b-E.sup.1b (I) wherein: W.sup.1a is ##STR02356## optionally substituted with one or more groups independently selected from the group consisting of halo, alkyl, haloalkyl, and cyano; X.sup.11 is --CH.sub.2--CH.sub.2--, --O--CH.sub.2--, or --CH.dbd.CH--; E.sup.1a is --N(H)(alkoxycarbonyl), --N(H)(cycloalkylcarbonyl) or --N(H)(cycloalkyloxycarbonyl); or E.sup.1a-V.sup.1a taken together are R.sup.9a; E.sup.1b is --N(H)(alkoxycarbonyl), --N(H)(cycloalkylcarbonyl) or --N(H)(cycloalkyloxycarbonyl); or E.sup.1b-V.sup.1b taken together are R.sup.9b; V.sup.1a and V.sup.1b are each independently selected from the group consisting of: ##STR02357## one of P.sup.1a and P.sup.1b is ##STR02358## and the other of P.sup.1a and P.sup.1b is selected from the group consisting of: ##STR02359## R.sup.9a and R.sup.9b are each independently: ##STR02360## or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein at least one of E.sup.1a and E.sup.1b is --N(H)C(.dbd.O)OCH.sub.3.

3. The compound of claim 1 wherein both of E.sup.1a and E.sup.1b are --N(H)C(.dbd.O)OCH.sub.3.

4. The compound of claim 1 wherein at least one of V.sup.1a and V.sup.1b is selected from the group consisting of: ##STR02361##

5. The compound of claim 1 wherein at least one of V.sup.1a and V.sup.1b is: ##STR02362##

6. The compound of claim 1 wherein at least one of V.sup.1a and V.sup.1b is selected from the group consisting of: ##STR02363##

7. The compound of claim 1 wherein V.sup.1a and V.sup.1b are each independently selected from the group consisting of: ##STR02364##

8. The compound of claim 1 wherein at least one of P.sup.1a and P.sup.1b is selected from the group consisting of: ##STR02365##

9. The compound of claim 1 wherein P.sup.1a and P.sup.1b are each independently selected from the group consisting of: ##STR02366##

10. A compound selected from the group consisting of: ##STR02367## ##STR02368## ##STR02369## ##STR02370## ##STR02371## ##STR02372## ##STR02373## ##STR02374## ##STR02375## ##STR02376## ##STR02377## ##STR02378## ##STR02379## ##STR02380## ##STR02381## ##STR02382## ##STR02383## ##STR02384## ##STR02385## ##STR02386## ##STR02387##

11. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable carrier.

12. The pharmaceutical composition of claim 11, further comprising at least one therapeutic agent.

13. The pharmaceutical composition of claim 12, wherein said therapeutic agent is a ribavirin analog, NS3 protease inhibitor, NS5b polymerase inhibitor, alpha-glucosidase 1 inhibitor, hepatoprotectant, non-nucleoside inhibitor of HCV, or other drug for treating HCV.

14. The pharmaceutical composition of claim 11, further comprising a nucleoside analogue.

15. The pharmaceutical composition of claim 14, wherein said nucleoside analogue is selected from the group consisting of ribavirin, viramidine, levovirin, a L-nucleoside, and isatoribine.

16. A method of treating hepatitis C virus in a human patient in need thereof, said method comprising administering to the patient a pharmaceutical composition which comprises a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc